Today in the Market (9/13/2023)

Good Evening! On Wednesday, markets were mixed, with investors paying particular attention to consumer inflation data, which has the potential to influence the Federal Reserve’s next policy choices.

The Dow Jones finished the day in the red, down 0.20%, while the S&P 500 increased by 0.12%. The Nasdaq Composite saw a modest gain of 0.29%.

GAS PAIN

The stocks of American Airlines (AAL) and Spirit Airlines (SAVE) saw a decline during trading on Wednesday. This decline was a result of both airlines revising their third-quarter projections due to the increasing costs of gasoline and recent decreases in airline ticket pricing.

So how much were the forecasts reduced?

  • Spirit’s current projection for third-quarter revenue is in the range of $1.24 billion to $1.25 billion, which is lower than the previous forecast of $1.3 billion to $1.32 billion.
  • American Airlines has revised its projected adjusted profits for the third quarter to be in the range of $0.20 to $0.30 per share, as opposed to the previously anticipated range of $0,85 to $0.95 per share.

Is gas really getting that expensive? Yes. The increase in gasoline expense at the airlines coincides with the current surge in oil prices, with the underlying commodity reaching its highest levels in 2023. The price of crude oil has seen an approximate increase of 30% since late June due to reductions in production and heightened worldwide demand.

NOSE CANDY?

A panel held by the FDA reached the conclusion that phenylephrine, the main component in several oral forms of well-known medications such as Sudafed, Benadryl, and Mucinex, failed to show benefit. Recent research findings indicate that those who were administered the medicine did not exhibit significantly improved sinus clarity compared to those who received a placebo, such as a sugar pill.

So what does this mean going forward? The decision on the removal of the drug’s over-the-counter safety designation will ultimately rest with the FDA. This would require the pharmaceutical firms to reformulate medications that include phenylephrine. Consequently, during this period of transition, drugs containing phenylephrine would be withdrawn from retail shelves.

What would happen if the FDA does ban the products? The implementation of a ban would have a significant impact on the medication manufacturing industry, with the sales of pharmaceutical products containing phenylephrine reaching around $2 billion in the year 2021, according to the FDA. Nevertheless, while oral phenylephrine may not effectively reduce congestion, it is widely considered that the nasal spray form of this medication remains effective.

Scroll to Top

Where Are You On Your Investment Journey?

Rise

Run

Relax

All investors are unique.  The above characteristics are examples, but may not reflect your particular investor demographics or situation.  An advisor with Edgar Investment Management, LLC will assist you with finding the best type of account for you. 

Investment advisory services are offered through Edgar Investment Management, LLC, an investment advisor registered with the State of Texas. Edgar Investment Management, LLC only offers investment advisory services where it is appropriately registered or exempt from registration and only after clients have entered into an investment advisory agreement confirming the terms of engagement and have been provided a copy of the firm’s ADV Part 2A brochure document.

The content found on this website is developed from sources we believe provide accurate information and is for educational purposes only. The information on this website is not intended as tax or legal advice. Everyone’s tax and legal situation is different, so please consult trusted and knowledgeable legal or tax professionals for specific information regarding your individual situation. The opinions expressed and material provided on this website are for general information, and should not be considered a solicitation for the purchase or sale of any security.

Material and information found on this website is not intended as an offer or solicitation for the sale or purchase of any specific security, mutual fund, ETF, bond, or investment strategy.  

Investing is risky!  No guarantee as to performance of any investment is implied by this website.  Make sure you have evaluated your options and spoken with trained professionals before you implement any investment strategy.  Past performance is not indicative of future results.  

Please be advised that Edgar Investment Management, LLC is a financial advisory firm specializing in investment management and financial planning services. We do not offer or provide any CPA-related services, including tax preparation, tax planning, or other accounting services. If you require assistance with tax-related matters, we recommend consulting a qualified CPA or tax professional who can provide specialized advice tailored to your individual needs.

Edgar Investment Management, LLC is not a Public Accounting firm.

 

Contact Us

Name
Best time(s) to contact you?
Best method(s) to contact you?

Contact Us

Name
Best time(s) to contact you?
Best method(s) to contact you?

We would love to hear from you! Please fill out this form and we will get in touch with you shortly.

  • About You

    Tell us a little about yourself. Don't be shy. Let's be friends.
  • How Can We Reach You?

    We would love to chat with you. How can we get in touch with you?
  • What's on your mind?

How much do you want to invest?